Literature DB >> 23220622

Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.

Alessandro Leuti1, Daunia Laurenti, Carmela Giampà, Elena Montagna, Clemente Dato, Serenella Anzilotti, Mariarosa A B Melone, Giorgio Bernardi, Francesca R Fusco.   

Abstract

In Huntington's disease (HD) mutant huntingtin protein impairs the function of several transcription factors, in particular the cAMP response element-binding protein (CREB). CREB activation can be increased by targeting phosphodiesterases such as phospohodiesterase 4 (PDE4) and phosphodiesterase 10A (PDE10A). Indeed, both PDE4 inhibition (DeMarch et al., 2008) and PDE10A inhibition (Giampà et al., 2010) proved beneficial in the R6/2 mouse model of HD. However, Hebb et al. (2004) reported PDE10A decline in R6/2 mice. These findings raise the issue of how PDE10A inhibition is beneficial in HD if such enzyme is lost. R6/2 mice and their wild type littermates were treated with the PDE10A inhibitor TP10 (a gift from Pfizer) or saline, sacrificed at 5, 9, and 13 weeks of age, and single and double label immunohistochemistry and western blotting were performed. PDE10A increased dramatically in the spiny neurons of R6/2 compared to the wild type mice. Conversely, in the striatal cholinergic interneurons, PDE10A was lower and it did not change significantly with disease progression. In the other subsets of striatal interneurons (namely, parvalbuminergic, somatostatinergic, and calretininergic interneurons) PDE10A immunoreactivity was higher in the R6/2 compared to the wild-type mice. In the TP10 treated R6/2, PDE10A levels were lower than in the saline treated mice in the medium spiny neurons, whereas they were higher in all subsets of striatal interneurons except for the cholinergic ones. However, in the whole striatum densitometry studies, PDE10A immunoreactivity was lower in the R6/2 compared to the wild-type mice. Our study demonstrates that PDE10A is increased in the spiny neurons of R6/2 mice striatum. Thus, the accumulation of PDE10A in the striatal projection neurons, by hydrolyzing greater amounts of cyclic nucleotides, is likely to contribute to cell damage in HD. Consequently, the beneficial effect of TP10 in HD models (Giampà et al., 2009, 2010) is explained by the efficiency of such compound in counteracting this phenomenon and therefore increasing the availability of cyclic nucleotides.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23220622     DOI: 10.1016/j.nbd.2012.11.016

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  10 in total

Review 1.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

Review 2.  Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.

Authors:  Antonella Cardinale; Francesca R Fusco
Journal:  CNS Neurosci Ther       Date:  2018-03-03       Impact factor: 5.243

3.  Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of DYT1 Dystonia.

Authors:  Vincenza D'Angelo; Valentina Castelli; Mauro Giorgi; Silvia Cardarelli; Ilaria Saverioni; Francesca Palumbo; Paola Bonsi; Antonio Pisani; Carmela Giampà; Roberto Sorge; Stefano Biagioni; Francesca R Fusco; Giuseppe Sancesario
Journal:  J Neurosci       Date:  2017-01-23       Impact factor: 6.167

4.  Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition.

Authors:  Sarah Threlfell; Anthony R West
Journal:  Basal Ganglia       Date:  2013-12-01

5.  Localization of neuroglobin in the brain of R6/2 mouse model of Huntington's disease.

Authors:  A Cardinale; F R Fusco; E Paldino; C Giampà; M Marino; M T Nuzzo; V D'Angelo; D Laurenti; G Straccia; D Fasano; D Sarnataro; T Squillaro; S Paladino; Mariarosa A B Melone
Journal:  Neurol Sci       Date:  2017-11-03       Impact factor: 3.307

Review 6.  Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models.

Authors:  Jordi Creus-Muncunill; Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

7.  Impaired TrkB Signaling Underlies Reduced BDNF-Mediated Trophic Support of Striatal Neurons in the R6/2 Mouse Model of Huntington's Disease.

Authors:  Khanh Q Nguyen; Vladimir V Rymar; Abbas F Sadikot
Journal:  Front Cell Neurosci       Date:  2016-03-09       Impact factor: 5.505

Review 8.  Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies.

Authors:  Chunchen Xiang; Shun Zhang; Xiaoyu Dong; Shuang Ma; Shuyan Cong
Journal:  Front Mol Neurosci       Date:  2018-05-15       Impact factor: 5.639

9.  Pyroptotic cell death in the R6/2 mouse model of Huntington's disease: new insight on the inflammasome.

Authors:  Emanuela Paldino; Vincenza D'Angelo; Giuseppe Sancesario; Francesca R Fusco
Journal:  Cell Death Discov       Date:  2020-07-31

10.  The Phosphodiesterase 10A Inhibitor PF-2545920 Enhances Hippocampal Excitability and Seizure Activity Involving the Upregulation of GluA1 and NR2A in Post-synaptic Densities.

Authors:  Yanke Zhang; Baobing Gao; Fangshuo Zheng; Shanshan Lu; Yun Li; Yan Xiong; Qin Yang; Yong Yang; Pengfei Fu; Fei Xiao; Xuefeng Wang
Journal:  Front Mol Neurosci       Date:  2017-04-07       Impact factor: 5.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.